Back to Search Start Over

Effect of Ibuprofen on Skeletal Muscle of Dysferlin-Null Mice.

Authors :
Collier AF
Gumerson J
Lehtimäki K
Puoliväli J
Jones JW
Kane MA
Manne S
O'Neill A
Windish HP
Ahtoniemi T
Williams BA
Albrecht DE
Bloch RJ
Source :
The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2018 Mar; Vol. 364 (3), pp. 409-419. Date of Electronic Publication: 2017 Dec 28.
Publication Year :
2018

Abstract

Ibuprofen, a nonsteroidal anti-inflammatory drug, and nitric oxide (NO) donors have been reported to reduce the severity of muscular dystrophies in mice associated with the absence of dystrophin or α -sarcoglycan, but their effects on mice that are dystrophic due to the absence of dysferlin have not been examined. We have tested ibuprofen, as well as isosorbide dinitrate (ISDN), a NO donor, to learn whether used alone or together they protect dysferlin-null muscle in A/J mice from large strain injury (LSI) induced by a series of high strain lengthening contractions. Mice were maintained on chow containing ibuprofen and ISDN for 4 weeks. They were then subjected to LSI and maintained on the drugs for 3 additional days. We measured loss of torque immediately following injury and at day 3 postinjury, fiber necrosis, and macrophage infiltration at day 3 postinjury, and serum levels of the drugs at the time of euthanasia. Loss of torque immediately after injury was not altered by the drugs. However, the torque on day 3 postinjury significantly decreased as a function of ibuprofen concentration in the serum (range, 0.67-8.2 µ g/ml), independent of ISDN. The effects of ISDN on torque loss at day 3 postinjury were not significant. In long-term studies of dysferlinopathic BlAJ mice, lower doses of ibuprofen had no effects on muscle morphology, but reduced treadmill running by 40%. Our results indicate that ibuprofen can have deleterious effects on dysferlin-null muscle and suggest that its use at pharmacological doses should be avoided by individuals with dysferlinopathies.<br /> (Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.)

Details

Language :
English
ISSN :
1521-0103
Volume :
364
Issue :
3
Database :
MEDLINE
Journal :
The Journal of pharmacology and experimental therapeutics
Publication Type :
Academic Journal
Accession number :
29284661
Full Text :
https://doi.org/10.1124/jpet.117.244244